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Abstract. The high-affinity Na+-dependent carnitine
transporter OCTN2 (SLC22A5) has a high renal
expression and reabsorbs most filtered carnitine. To
gain more insight into substrate specificity of OCTN2,
we overexpressed hOCTN2 in L6 cells and charac-
terized the structural requirements of substances
acting as human OCTN2 (hOCTN2) inhibitors. A
1905-bp fragment containing the hOCTN2 complete
coding sequencewas introduced into the pWpiresGFP
vector, and L6 cells were stably transduced using a
lentiviral system. The transduced L6 cells revealed
increased expression of hOCTN2 on the mRNA,
protein and functional levels. Structural requirements
for hOCTN2 inhibition were predicted in silico and
investigated in vitro.Essential structural requirements
for OCTN2 inhibition include a constantly positively
charged nitrogen atom and a carboxyl, nitrile or ester
group connected by a 2–4-atom linker.Our cell system
is suitable for studying in vitro interactions with
OCTN2, which can subsequently be investigated in
vivo.
Keywords. hOCTN2, secondary carnitine deficiency, drug-carnitine interactions, stable transfection, acylcarni-
tines, verapamil.
Introduction
Carnitine is essential for the transport of activated
long-chain fatty acids into themitochondrial matrix of
most cell types, where they can be metabolized by b-
oxidation [1, 2]. Beside its role in the transport of long-
chain fatty acids, carnitine also enables the removal of
potentially toxic short acyl groups, e.g., acetate or
propionate, from the mitochondrial matrix and/or
cytosol [3, 4].
Loss of carnitine from the body is minimized by the
Na+-dependent high-affinity carnitine transporter
OCTN2, which is primarily responsible for reabsorp-
tion of filtered carnitine in the kidney [5–8]. The
importance of this carnitine transporter becomes
apparent from the severe consequences of OCTN2-
related disorders. In primary systemic carnitine defi-
ciency (CDSP, OMIM 212140) [1, 4–9], caused by
mutations in the SLC22A5 gene encoding forOCTN2,
cellular (re)-uptake of carnitine is impaired [10–15].
Clinical findings in patients with primary carnitine
deficiency result from low tissue carnitine levels and
include myopathy, cardiomyopathy, hepatomegaly
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and failure to thrive [15–17]. Mutations in SLC22A5
(OCTN2) found more recently were also associated
with peripheral neuropathy [18] and ventricular
fibrillation [19].
Besides the well-known roles of carnitine, several
studies suggest that carnitine is involved in amultitude
of other processes, for instance sperm quality assur-
ance, immune responses or myocardial integrity and
function, explaining the large interest for carnitine
and OCTN2 [20–22].
Various drug interferences with carnitine transport
[23–25] have been reported to cause secondary
carnitine deficiency. Interference of various xeno-
biotics with OCTN2 has been characterized by Ohasi
et al. [26]. Cephalosporin antibiotics comprising a
quaternary nitrogen have been shown to inhibit
OCTN2-mediated carnitine reabsorption in the kid-
ney [27]. Structural features in these compounds
mimicking physicochemical properties of carnitine
may be responsible for inhibition of carnitine trans-
port by OCTN2. Alternatively, allosteric interactions
between xenobiotics and human OCTN2 (hOCTN2)
may also be possible. Such drug-carnitine interactions
may impair renal reabsorption of carnitine, possibly
resulting in secondary carnitine deficiency.
In the present study, the transport characteristics of
carnitine into different cell lines were determined to
identify a suitable cell line for overexpressing
hOCTN2. Subsequently, a stably transfected cell line
was established, allowing the study of hOCTN2-
driven carnitine transport. Some functional character-
istics of this artificial hOCTN2 system were assessed
and kinetic parameters of L-carnitine transport de-
termined. Furthermore, this system enabled us to test
the functionality of hOCTN2 in the presence of a
variety of carnitine analogues as well as compounds
comprising quaternary ammonium groups without
structural similarity to carnitine and other compounds
lacking structural similarities to carnitine.
Materials and methods
Reagents.All chemicals were purchased from Sigma,
except L-carnitine, which was obtained from Fluka
(Buchs, Switzerland). L-[3H]carnitine hydrochloride
(81 Ci/mmol) was obtained fromAmersham-Pharma-
cia Biotech (Little Chalfont, Buckinghamshire, UK).
Trimethylhydrazinium propionate was synthesized as
described previously [28].
Cell culture. L6 cells (rat skeletal muscle myoblasts,
obtained from American Type Culture Collection,
Rockville, USA) and EBNA cells (human primary
embryonal kidney, also from American Type Culture
Collection) were grown in Dulbeccos modified
Eagles medium (DMEM), supplemented with 10%
fetal bovine serum (FBS), 1 mM sodium pyruvate and
100 U/ml penicillin and 100 mg/ml streptomycin (all
substances from Invitrogen, Switzerland) at 378Cwith
5% CO2 and 95% humidity.
Preparation of polyclonal antibodies against OCTN2.
The polyclonal antibody anti-OCTN2/K33 was gen-
erated to recognize a C-terminal amino acid sequence
of the rat OCTN2 (amino acids 543–557). The peptide
was coupled at the N terminus to keyhole limpet
hemocyanin (KLH) to increase its immunogenicity.
The structure of the construct was as follows: KLH-
Tyr-Lys-Asp-Gly-Gly-Glu-Ser-Pro-Thr-Val-Leu-Lys-
Ser-Thr-Ala-Phe-COOH. Rabbits were immunized
and serum obtained as described previously [29].
Characterization of the antibodies. The antibodies
were characterized byWestern blotting of human and
rat tissues, peptide competition and in situ hybrid-
ization in rat tissue. Male Sprague Dawley rats
(150–200 g) housed under standard conditions were
killed by decapitation, tissues were excised and
immediately frozen in liquid nitrogen. Human tissues
were obtained from cadavers <20 h post mortem
(Institute of Pathology, University Hospital, Basel).
For Western blotting, tissues were homogenized at a
concentration of 1 g/6 ml with a polytron homoge-
nizer (Kinematica, Switzerland) in cold homogeni-
zation buffer [20 mM Tris-HCl pH 6.8, 1% SDS,
1 mM DTT, containing Complete Mini anti-pro-
tease cocktail (Roche, Switzerland)] and centrifuged
(700 g, 5 min) at 48C. Homogenate (50 mg protein)
was combined with the same volume of loading
buffer (2% SDS, 10% glycerol, 100 mM Tris-HCl
pH 6.8, bromophenol blue, 5 mM DTT), heated to
508C for 3 min and loaded onto a 10% SDS-
polyacrylamide gel. Proteins were separated in Tris-
glycine running buffer (25 mM Tris, 192 mM glycine,
0.1% SDS, pH 8.3) and transferred to nitrocellulose
filters (Hybond ECL, APBiotech, Piscataway, USA)
using a wet-transfer cell (Bio-Rad, Reinach, Switzer-
land) in a buffer containing 25 mM Tris, 192 mM
glycine, pH 8.3, and 10% methanol (1 h, 400 mA).
The filter was blocked in 3%defattedmilk powder in
PBS and exposed to the primary antibody anti-
OCTN2/K33 antiserum (1:1000) in PBS/milk for 2 h.
Secondary horseradish peroxidase-conjugated anti-
body to rabbit IgG (APBiotech) was used 1:5000 for
30–45 min in PBS/milk and the blot was rinsed four
times in PBS/milk and twice in PBS. Antibody
binding was visualized with an ECL detection system
(APBiotech).
Cell.Mol. Life Sci. Vol. 65, 2008 Research Article 1597
For peptide competition experiments, anti-OCTN2/
K33 rabbit serum was preincubated with an excess of
either the specific immunogen or a similar nonspecific
peptide. Briefly, 2 ml rabbit sera (30 mg or 200 pmol
IgG) was pre-adsorbed with 50 mg (30 nmol) of the
nonspecific antigen K34/OCTN2 (KLH-Tyr-Leu-Pro-
Asp-Thr-Ile-Asp-Gln-Met-Leu-Arg-Val-Lys-Gly-Ile-
Lys-COOH) or specific antigen (K33/OCTN2) at
room temperature in 500 ml PBS for 2 h. Two nitro-
cellulose filters were prepared containing electro-
phoresed samples (25–50 mg) of a rat kidney heavy and
a rat kidney light membrane fraction (see below).
After 2 h, the volume of the antigen-antibody solution
was made up to 4 ml in PBS 3%milk (1:2000 dilution
of sera) and applied separately to one of the nitro-
cellulose filters. The filters were incubated for 2 h
room temperature with either one of the pre-adsorbed
antisera, washed and detection continued using a
normal Western blotting procedure.
For the preparation of the membrane fractions, 1 g rat
kidney was cut frozen (–708C), minced with scissors
and homogenized with a polytron in 6 ml ice-cold
homogenization buffer (0.25 M sucrose, 10 mM Tris-
HCl pH8, anti-protease cocktailRoche). The resulting
homogenate was centrifuged at 800 g 48C for 5 min
and the supernatant centrifuged at 10 000 g 48C for
15 min. The supernatant was then subjected to a
150 000 g spin for 1 h in a Beckman ultracentrifuge
(SW55Ti rotor, Beckman, Nyon, Switzerland) and the
resulting pellet was resuspended in 1 ml homogeniza-
tion buffer containing 8% (w/v) sucrose and loaded
onto a sucrose gradient (20/30/40/50/70% w/v sucrose
in Tris buffer, pH 8). The gradient was spun for 18 h at
80 000 g in a swing out rotor (SW28 rotor, Beckman)
and the visible protein fractions at the 40/50%
(fraction 4 = heavy fraction, k4) and at the 20/30%
interface (fraction 6 = light fraction, k6) were
collected, diluted in Tris buffer pH 8 (no sucrose)
and pelleted at 100 000 g for 1 h. The pellets were
resuspended in 100–1000 ml homogenization buffer
and the protein concentration assayed (Bio-Rad
protein assay reagent using BSA as a standard). The
heavy membrane fraction gave a strong signal with
antibodies against Na+/K+ ATPase and aminopepti-
dase N, indicating a high brush border membrane
content (data not shown). In the lighter membrane
fraction, these signals were less pronounced (not
shown).
For in situ hybridization experiments, rat and human
tissues were freshly collected, cut into 2–3-mm cubes,
and placed into 4% paraformaldehyde in PBS for
3–16 h at 48C with gentle shaking for fixation. Tissues
were rinsed in multiple changes of PBS and stored in
25% PVP-10 sucrose in PBS, 48C overnight. Tissues
were mounted on silane-coated slides and sections
blocked prior to labeling with a 1:20 solution of goat
serum in PBS/BSA blocking solution. Immunolabel-
ing was performed at room temperature and anti-
bodies diluted in wash solution (PBS + 0.5% BSA).
Primary antibody was anti-OCTN2/K33 1:200 and
secondary antibody was Cy2-labeled goat anti-rabbit
1:300. Wash steps were for 15 min with four to five
changes of buffer, primary antibody was allowed to
bind for 1 h and the secondary for 30–45 min insulated
from light. The labeled coverslips were mounted onto
glass slides and allowed to set before visualizing. The
slides were viewed using a Zeiss axiophot fluorescent
microscope and images taken with analySIS software
(Zeiss Instruments, Heerbrugg, Switzerland).
Production of lentiviral vectors and transduction of L6
cells. A 1905-bp fragment containing the hOCTN2
complete coding sequence was isolated from EBNA
cells and introduced into the pWpiresGFP vector
(kind gift of Dr. Didier Trono, University of Geneva).
The new recombinant plasmid was verified on muta-
tions by DNA sequencing. Lentiviral vector envelope
plasmid pMD2.G and packaging plasmid
pCMCDR8.91 were kindly provided by Dr. Didier
Trono. For the production of HIV-derived vectors, the
envelope plasmid pMD2.G, the packaging plasmid
pCMCDR8.91 and the vector plasmid pwPhOCT-
N2iresGFP (or empty vector pwPiresGFP) were
introduced into 293T cells by calcium phosphate
precipitation as described [30]. After 12 h themedium
was replaced. The supernatant was harvested at 38 h
post transfection, centrifuged at 2500 rpm, filtered
through a 0.45-mM filter and stored at 48C. Fresh
medium was added to the cells and, after 24 h, the
harvest procedure repeated. The viral stocks were
pooled, aliquoted and stored at –708C.
Expression of hOCTN2 in L6 cells. L6 cells, grown to
about 50% confluency in six-well plates, were incu-
bated with virus supernatant prepared as detailed in
the preceding section in the presence of Polybrene
(Aldrich, Buchs, Switzerland). Success of transduction
was estimated with fluorescence-activated cell sorting
(FACS) analysis. Enhanced green fluorescent protein
(EGFP)-positive cells were enriched byFACS and cell
culture was continued with this population.
Expression of hOCTN2 in the transduced L6 cells was
determined with quantitative real-time PCR. Total
RNA was isolated with RNeasy (Qiagen, Basel,
Switzerland) as described by themanufacturer. Super-
script TM II together with oligo(dT) and Random
Hexamer primers (Gibco BRL, Basel, Switzerland)
was used for reverse transcription of 2 mg total RNA.
Quantification was performed on a ABI PRISM 7700
Sequence Detector (PE Biosystems, Rotkreuz, Swit-
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zerland). Reporter probes hOCTN2 and GAPDH
FAM/TAMRAwere from Eurogentec (Seraing, Bel-
gium); the hOCTN2 and GAPDH forward and
reverse primers were from Microsynth (Balgach,
Switzerland). PCR conditions were 958C for 10 min,
preceded by a 2-min step at 508C, and 40 cycles 958C
for 10 s, 608C for 60 s. The total reaction volume was
25 ml. For each cell type, a serial dilution of DNAwas
used (range: 6.25–50 ng) to investigate whether the CT
method could be used for calculation. GAPDH
primers and probe were: forward primer 5-
GGTGAAGGTCGGAGTCAACG-3 and reverse
primer: 5-ACCATGTAGTTGAGGTCAATGAA-
ACHTUNGTRENNUNG G-3 and the probe 5-CGCCTGGTCAC-
CAGGGCTGC-3. The primers for the carnitine
transporter hOCTN2 were designed to amplify a
region that is highly conserved between human and
rodent species. The forward primer was 5-C(A or
C)TATGTGTTGGCCTGGCTG-3, the reverse pri-
mer ACHTUNGTRENNUNG5-AACTTGCCCACCATCACCAG-3 and the
probe ACHTUNGTRENNUNG5-CTCTTCCTGGGTGGCAGTGTCCTT-
ACHTUNGTRENNUNG TCT-3.
Flow cytometry analysis and immunohistochemistry
of L6 cells overexpressing hOCTN2. For immunohis-
tochemistry, cells were grown for 24 h at 378C in an
eight-chamber slide coated with poly-D-lysine. After
washing, cells were visualized by phase-contrast
microscopy and, after incubation with anti-OCTN2
(1:200, 30 min) and/or fluorescent-labeled Cy3 sheep
anti-rabbit Ig (1:300, 20 min), by fluorescence micro-
scopy (Olympus IX 50, Hamburg, Germany).
For flow cytometry, cells were rinsed with PBS and
harvested with 10 mM EDTA. The detached cells
were pelleted, resuspended in PBS supplementedwith
2%FBS, and passed through a filter (40 mM) to obtain
single cells. Cells were fixed with 2% paraformalde-
hyde for 20 min, washed and incubated with anti-
OCTN2 antiserum anti-OCTN2/K33 (1/200 dilution)
for 30 min. Cells were washed again before adding the
fluorescent-labeled Cy3 sheep anti-rabbit Ig (Sigma)
for 20 min. For analytical cell sorting, 2104 cells were
used on a FACSCalibur analyzer (Becton Dickinson,
Allschwil, Switzerland).
Functional characterization of L6 cells overexpressing
hOCTN2.The functionality of the hOCTN2 construct
was evaluated by L-[3H]carnitine transport measured
at 308C. Cells were grown to confluency on 12-well
plates (Becton Dickinson), washed twice with pre-
warmed sodium uptake buffer (116 mM NaCl,
5.3 mM KCl, 0.8 mM MgSO4, 26.2 mM NaHCO3,
1 mM NaH2PO4 , 5.5 mM D-glucose, pH 7.4) and
then incubated for 5 min in 2 ml of this buffer. The
total uptake of L-[3H]carnitine was determined by
incubating the cells with 0.5 ml sodium uptake buffer
containing 50 mML-carnitine (5 mCi/0.5 ml) for 8 min
at 308C. The uptake was stopped by the addition of
2 ml ice-cold choline wash buffer (116 mM choline
chloride, 5.3 mM KCl, 0.8 mM MgSO4, 26.2 mM
choline bicarbonate, 1 mM KH2PO4 , 5.5 mM D-
glucose and 1 mML-carnitine, pH 7.4). After washing
the cells twice with 2 ml ice-cold choline uptake
buffer, they were solubilized with 1 ml 1% SDS (w/v).
After addition of 5 ml scintillation fluid (Ultima-
goldTM, Packard Bioscience, Zrich, Switzerland), the
cell-associated radioactivity was counted.
For the sodium-independent L-carnitine uptake, the
sodium uptake buffer was replaced by choline uptake
buffer (does not contain L-carnitine, but is otherwise
identical with the choline wash buffer). Otherwise the
same procedure was applied.
The sodium-dependent L-carnitine uptake was ob-
tained as the difference between total L-carnitine
uptake (L-carnitine uptake determined in the pres-
ence of the sodium uptake buffer) and sodium-
independent L-carnitine uptake.
In experiments dealing with inhibition of transport,
cells were preincubated for 15 min with 0.1 and
1.0 mM (or 0.05 and 0.5 mM) inhibitor candidates
before starting the uptake experiments executed as
described above.
The protein concentration was determined using the
BCA assay (Pierce, Rockford, IL, USA).
Search for compounds mimicking carnitine. At first,
known substrates of OCTN2 that interfere with the
transport of L-carnitine were analyzed to identify
common structural features that might be responsible
for this behavior. Superposition of an energy-mini-
mized 3D structure of L-carnitine on aX-ray structure
of cephaloridine revealed a good match of the
positively charged tetramethylammonium group and
the carboxylate group of L-carnitine with the charged
pyridinium nitrogen and the carboxylate groups in the
antibiotic, respectively (Fig. 1A). The 3D structure of
cephaloridine was obtained from the Cambridge
Structural Database (CSD) [31]. It was tempting to
assume a functional role for both the negatively
ionizable carboxylate and the constantly positively
charged ammonium groups, and thereby identifying
critical pharmacophores in the interaction of L-
carnitine with OCTN2 (Fig. 1B).
Subsequently, the Merck index [32] was searched for
compounds comprising such a pharmacophore pat-
tern with more or fewer constraints for the distance
between the negative and positive charges (linker of
two to six saturated C-C bonds). Further compounds
were identified in the “Index Nominum 2000” (http://
www.micromedex.com/products/indexnominum/).
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Selected substances were divided into four groups
(Fig. 1C): (1)Molecules comprising an ammonium ion
connected to a carboxylic acid with a three- to five-
atom linker; (2) molecules comprising ammonium
ions and derivatives thereof but not bearing a
carboxylic acid group; (3) molecules comprising a
positively charged nitrogen in a heteroaromatewith or
without a carboxylic acid group; and (4) cephalospor-
ins or other compounds lacking a permanently
positive charge (Fig. 1C).
Selected substances were then tested for their inhib-
itory effect on L-carnitine transport using L6 cells
overexpressing hOCTN2. The transport activity of L-
carnitine was determined as described before.
Possible interactions between cefalotin and L-carni-
tine. Possible interactions between cefalotin and L-
carnitine were studied by assessing the effect of L-
carnitine on the absorption spectrum of cefalotin and
by assessing the effect of cefalotin on the L-carnitine
concentration during the L-carnitine transport experi-
ments.
For studying the effect of L-carnitine on the absorp-
tion spectrum of cefalotin, cefalotin was dissolved at
two concentrations (100 and 1000 mmol/l, respective-
ly) in sodium uptake buffer (116 mM NaCl, 5.3 mM
KCl, 0.8 mMMgSO4, 26.2 mMNaHCO3, 1 mMNaH2
PO4 , 5.5 mM D-glucose, pH 7.4) and the absorption
spectrum was obtained between 190 and 600 nm.
After the addition of 100 mmol/l L-carnitine, the same
absorption spectrum was obtained and the spectra
were compared.
To investigate a possible effect of cefalotin on the
degradation of L-carnitine, L6 cells overexpressing
hOCTN2were incubated in sodiumuptake buffer (see
above) containing different cefalotin concentrations
(0, 100 or 1000 mmol/l) at 308C. After the addition of
L-carnitine (25 or 50 mmol/l), L-carnitine transport
was allowed to proceed for 8 min. After this time, the
reactions were stopped by centrifugation of the
suspensions (10 000 g at 58C for 1 min). The concen-
trations of free and total acid soluble carnitine were
measured in the supernatant as described byBrass and
Hoppel [33].
Kinetic analysis and statistic. The kinetic parameters
of L-carnitine transport into L6 cells transfected with
hOCTN2 were calculated using the program sigma-
plot version 10 (Scientific Solutions, www.scientific-
solutions.ch). After subtraction of the values obtained
in the presence of choline from those in the presence
of sodium, data were fitted using nonlinear least
squares regression analysis to:
v ¼ Vmax  S
Km þ S
where v and S are the uptake rate and the concen-
tration of L-carnitine, respectively, Vmax is the max-
imal transport rate for L-carnitine and Km the
Michaelis-Menten constant.
For the determination of the IC50 value for verapamil,
the data were fitted to:
Activity ¼ maxmin
1þ ðx=IC50ÞHillslope
using sigmaplot version 10. Max is maximal activity
(inhibitor concentration zero), min is the minimal
activity, x is the concentration of the inhibitor, IC50 the
concentration of the inhibitor at 50% inhibition of the
activity and Hillslope the slope of the curve. Data are
presented as mean  standard deviation.
Results
Production and characterization of antibodies against
OCTN2. One of two rabbits immunized developed
antibodies against a protein of 67 kDa on theWestern
blot of rat kidney and rat kidney brush border
membrane vesicles (data not shown). Further charac-
terization of the antiserum (anti-OCTN2/K33) ob-
tained from this rabbit showed that it also reactedwith
human kidney tissue (onWestern blots) obtained post
mortem (data not shown).
To demonstrate the specificity of the anti-OCTN2/
K33 serum, a competition experiment with the pep-
tide used for immunization was performed. As shown
in Figure 2A (panel a), K33 pre-treated with an
unspecific peptide identifies a 67-kDa protein in the
k4 fraction of rat kidney. This band (indicated by an
arrow) can also be detected in the k6 fraction, but is
much fainter. After pre-treatment of anti-OCTN2/
K33 with the peptide used for antibody production,
both bands at 67 kDa vanished (Fig. 2A, panel b).
Finally, as shown in Figure 2B, immunohistochemistry
of rat kidney sections showed the expected local-
ization of OCTN2 on the luminal side of proximal
tubules. Similar results were obtained with human
kidney (results not shown).
Characterization of hOCTN2 expression in stably
transduced L6 cells.FACS analysis revealed a primary
success rate of transduction of approximately 60% in
L6 cells. Cells were cultured and characterized first by
mRNA expression of hOCTN2 using RT-PCR. Quan-
titative real time PCR showed a>250-fold increase of
hOCTN2mRNA expression in L6 transfected cells as
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compared to mock transfected L6 cells (not shown).
The presence of the hOCTN2 transporter was further
demonstrated by immunohistochemistry (Fig. 3A)
and by FACS analysis (Fig. 3B).
The functionality of the hOCTN2 construct in L6 cells
was evaluated by L-[3H]carnitine uptake experiments,
where, for assessing the sodium-independent uptake,
Na+ was replaced by choline in the transport buffer.
We found the Na+-dependent L-[3H]carnitine uptake
to be approximately 25-fold higher in hOCTN2
transduced L6 cells as compared to mock transfected
L6 cells after 8 min of exposure at 308C (Fig. 4A). In
contrast, the Na+-independent transport activity re-
mained unchanged in transducedL6 cells as compared
to the mock-transfected L6 cells. The uptake was
linear for at least 8 min.
Next, the concentration dependency of the L-carni-
tine transport was determined and kinetic parameters
were calculated. As shown in Figure 4B, the transport
of L-carnitine was saturable after correction for a non-
saturable component. The calculated Km and Vmax
values for L-[3H]carnitine transport are 9.70.3 mM
and 2904 pmol/mg protein/min, respectively.
Inhibitors of carnitine transport by hOCTN2. Four
groups of compounds were selected as described in
Material and methods, and subsequently tested for
their capacity to interfere with L-carnitine transport
by hOCTN2. Derivatives of L-carnitine and close
structural analogs (group 1, e.g., acylcarnitines, butyr-
obetaine and trimethylhydrazinium propionate) dem-
onstrated a strong inhibition of the L-carnitine uptake
by transfected L6 cells (Table 1). The nature of the
atoms linking the charged group is not of critical
importance for recognition by hOCTN2 (compare L-
carnitine vs trimethylhydrazinium propionate). How-
ever, a linker length of at least three atoms between
ammonium ion and carboxylate is crucial for recog-
nition by the transporter, as is clearly indicated by the
lack of interaction for betaine that comprises only a
short linker. Substituents of different length connect-
ed to the linker are tolerated by hOCTN2without loss
of inhibition, unless the substituent is branched
(Table 1, compare hexanoylcarnitine vs valproylcar-
nitine, pivaloylcarnitine). Interestingly, removal of a
single methyl group and thereby the constant charge
from the ammonium functionality results in complete
loss of inhibitory power (Table 1, compare butyrobe-
taine vs dimethylaminobutyric acid). Replacement of
the negatively charged carboxylate by an ester or
inverted ester group did not decrease the inhibitory
activity, as long as the linker consisted of at least three
atoms (Table 2, e.g., atropine methyl bromide, aniso-
tropine methyl bromide, ipratropium bromide). Ap-
Figure 1. Characterization of the substances used as potential inhibitors of hOCTN2. (A) Superposition of L-carnitine (blue) on
cephaloridine (green), showing the structural similarity. (B) L-carnitine (blue) with the two pharmacophores postulated: the ammonium
functionality (red ball) and the carboxyl group (green ball). (C) The substances selected based structural similarity with L-carnitine and
tested for inhibition of L-carnitine transport were (1) substances containing an ammonium ion connected to a carboxylic acid with a three-
to five-atom linker, (2) ammonium ions and derivatives thereof not linked to a carboxylic acid group, (3) substances comprising a positively
charged nitrogen in a heteroaromate with or without a carboxylic acid group, and (4) substances lacking a constantly positive charge (e.g.,
cephalosporins, verapamil). Typical representatives of each group are shown.
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parently, the inactive scopolamine butyl bromide
seems to disobey this rule; however, this lack of
interaction with hOCTN2 may be a consequence of
the extended alkyl group attached to the ammonium
ion (Table 2, compare scopolaminemethyl bromide vs
scopolamine butyl bromide). Neostigmin bromide
showed no inhibitory activity, either due to the
exchange of the ester to a carbamate group or due to
its very rigid geometry that could prevent productive
interaction with the protein. Shortening the distance
between ammonium ion and inverted ester or remov-
ing the ester function resulted in loss of the inhibitory
activity (Table 2, see acetylcholine, carbamylcholine,
decamethonium bromide).
Incorporation of the positive charge into a heteroar-
omate resulted in a substantial or complete loss of the
inhibitory activity (Table 3). Interestingly, of the two
cephalosporins comprising a constant positive charge
only cefozopran showed a weak inhibitory activity,
while ceftazidime did not interfere with L-carnitine
transport at all, despite the presence of a three-atom
linker between the charged pyridinium nitrogen and
carboxylate. Pancuronium bromide displayed an un-
expected weak inhibitory activity, despite comprising
only a short two-atom linker between ammonium ion
and inverted ester. Not surprisingly, pyridostigmine
bromide comprising only a short linker as well as
amprolium hydrochloride and hexadecylpyridinium
bromide, which both lack the carboxylic acid func-
tionality, were completely inactive.
All substances lacking the constantly ionized nitrogen
were completely inactive up to this point (see Table 4
and dimethylaminobutyric acid in Table 1). One sub-
stance not following this rule was cefalotin, which
appeared to stimulate transport of L-carnitine by
OCTN2. To study the possible formation of a complex
between cefalotin and L-carnitine, the absorption spec-
trum of cefalotin (100 or 1000 mmol/l) was obtained in
the absence and presence of 100 mmol/l L-carnitine.
Since the addition of L-carnitine did not change the
absorption spectrumof cefalotin (data not shown), the
formation of a complex between the two compounds
Figure 2. Characterization of
the antiserum against a polypep-
tide of the preterminal region of
rat OCTN2 (anti-OCTN2/K33).
(A) Anti-OCTN2 serum treated
with an unspecific peptide iden-
tifies a 67-kDa protein in the k4
(heavy membrane fraction) and,
fainter, in the k6 fraction (light
membrane fraction) of rat kid-
ney (panel a). After pre-treat-
ment of anti-OCTN2 serum with
the peptide used for antibody
production, both bands at
67 kDa have vanished (panel b).
(B) Immunohistochemistry of
rat kidney sections shows the
expected localization of OCTN2
on the luminal side of proximal
tubular cells in sections treated
with anti-OCTN2 serum (pri-
mary antibody) and Cy2-labeled
goat anti-rabbit (secondary anti-
body) (panel b). In sections treat-
ed with secondary antibody only,
the fluorescence pattern is un-
specific (panel a).
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could be excluded under the conditions used. Fur-
thermore, a possible inhibition of L-carnitine degra-
dation by cefalotin was studied in incubations con-
taining different L-carnitine (25 or 50 mmol/l) and
cefalotin concentrations (0, 100, 1000 mmol/l). The
results showed that L-carnitine is not degraded under
the conditions studied and that cefalotin has no effect
on L-carnitine degradation (data not shown), exclud-
ing this possibility as a reason for the observed
increase in carnitine transport in the presence of
cefalotin.
Another molecule behaving against the rule that a
positive charge is required for interference with L-
carnitine transport by OCTN2 was verapamil. In
agreement with a previous report [34], verapamil
hydrochloride was found to be a strong inhibitor of
hOCTN2 (Fig. 1C). To further characterize this in-
hibitory effect exerted by verapamil, the IC50 was
determined to be 5.3 mM (Fig. 5). In this context, the
complete lack of inhibitory activity of dimethylami-
nobutyric acid is remarkable, considering its close
topological relationship with the highly active butyr-
obetaine. In general, a permanent positive charge
appears to be crucial for a compound interfering with
L-carnitine transport by hOCTN2.
Discussion
The membrane protein OCTN2 is a member of the
sodium-dependent organic cation transporters, with a
high affinity for L-carnitine. In humans, OCTN2 is
expressed strongly in kidney but only weakly in
skeletal muscle, liver, lung, brain and small intestine
[6], whereas the rat counterpart is highly expressed in
Figure 3. Morphological characterization of the L6 cells trans-
fected with hOCTN2. (A) Cells were grown in an eight-chamber
slide, washed and visualized by phase contrast microscopy (panel
a). Other slides were incubated with anti-OCTN2 (1:200, 30 min)
and/or fluorescent-labeled Cy3 sheep anti-rabbit Ig (1:300, 20 min)
and assessed by fluorescence microscopy (panels b–d). A positive
result by fluorescence microscopy is seen only in L6OCTN2GFP
cells treated with the combination anti-OCTN2 and Cy3 sheep
anti-rabbit Ig (panel c). (B) Cells were detached with 10 mM
EDTA, fixed with 2% paraformaldehyde for 20 min, washed and
incubated first with anti-OCTN2 antiserum (anti-OCTN2/K33,
1:200 dilution) and then with Cy3-labeled sheep anti-rabbit Ig. For
analytical cell sorting, 2104 cells were used on a FACSCalibur
analyzer. There is a clear shift of the signal in L6OCTN2GFP cells
compared to L6GFP cells.
Figure 4. Functional characterization of the L6 cells overexpressing hOCTN2. The functionality of hOCTN2 was determined by L-
[3H]carnitine uptake experiments as described in Methods. (A) Time dependency of sodium-dependent L-carnitine transport. While no
sodium-dependent transport of L-carnitine canbedetected in non-transfectedL6 cells or L6 cells transfectedwithGFP, L6 cells transfected
with hOCTN2/GFP have a high sodium-dependent transport activity, which is linear up to at least 8 min. (B) Assessment of the kinetics of
L-carnitine transport into L6OCTN2GFP cells revealed saturable sodium-dependent transport of L-carnitine after correction for the
sodium-independent component. The calculated Km and Vmax values for L-[
3H]carnitine transport are 9.70.3 mM and 2904 pmol/mg
protein/min, respectively.
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kidney and testis, but to a lesser extent in liver and
small intestine [28, 35].
The substrate specificity of OCTN2 is broad, as
several other cations, in particular carnitine deriv-
atives and carnitine analogues are able to compete
with and inhibit L-carnitine transport [7] . We
therefore established and characterized a heterol-
ogous expression system designed for measuring
transport inhibition of L-carnitine by compounds
with more or less structural similarity. The strong
inhibition exhibited by some of these selected
compounds (Table 1) is consistent with reports
found in the literature [7, 26, 36, 37] . Surprisingly,
also therapeutics interfere with OCTN2-mediated
L-carnitine transport [34] , among them some mem-
bers of the cephalosporin family as reported by
Ganapathy et al. [27] .
The interaction of certain cephalosporins with the
OCTN2 transporter can most likely be attributed to
the presence of a pharmacophore pattern (Fig. 1B) in
the substances that mimic L-carnitine. As a working
hypothesis, we assumed the pharmacophore pattern to
consist of a quaternary nitrogen that is separated by
three atoms from a carboxylic acid functionality,
thereby mimicking the topology of L-carnitine. To
test this hypothesis and to explore its rigidity, we
selected compounds and divided them into four
categories of as described in the results section.
Carnitine and close derivatives thereof (Table 1) have
all a very profound inhibiting effect on L-carnitine
Figure 5. Inhibition of hOCTN2-
driven transport of L-carnitine by
verapamil. To investigate the inter-
action between hOCTN2 and ve-
rapamil in more detail, L-carnitine
transport by L6 cells overexpress-
inghOCTN2was studiedat several
verapamil concentrations (A) and
the IC50 was determined (B). L-
carnitine transportwas determined
as described in Methods and incu-
bations containing excess L-carni-
tine were used as controls. Verapa-
mil turned out to be a potent
inhibitor L-carnitine transport
with an IC50 of 5.3 mmol/l.
Table 1. Inhibition of hOCTN2 by substances carrying an ammonium ion and a carboxylic acid group. Inhibition was scored as follows: -,
>80% hOCTN2 activity in the presence of 100 or 1000 mM potential inhibitor; +, <80% and >50% hOCTN2 activity in the presence of
1000 mM inhibitor; ++, <50% hOCTN2 activity in the presence of 1000 mM inhibitor; +++, <50% hOCTN2 activity in the presence of
100 mM inhibitor.
Substance Carnitine transport
(% of control, inhibitor
100 mM)
Carnitine transport
(% of control, inhibitor
1000 mM)
No. of atoms between
pharmacophores
Efficacy of
inhibitor
L-carnitine 494 15 3 +++
Acetylcarnitine 782 231 3 ++
Pivaloylcarnitine 911 564 3 +
Hexanoylcarnitine 591 130 3 ++
Octanoylcarnitine 633 181 3 ++
Valproylcarnitine 968 773 3 +
Palmitoylcarnitine 805 20? 3 ++
Trimethylhydrazonium
propionate
920 342 3 ++
Butyrobetaine 573 161 3 ++
Dimethylaminobutyric acid 1021 942 3 –
Betaine 1121 1064 1 –
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transport by hOCTN2. A linker of three atoms
between the two functionalities (ammonium ion,
carboxylic acid) appears to be critical as exemplified
by the short-linked betaine being completely inactive.
Substitutions at the linker are neither required nor
forbidden and therefore without importance, as
evidenced for butyrobetaine and trimethylhydrazini-
um propionate. Even long substituents such as palm-
itoyl are well tolerated as long as they are unbranched.
The slightly decreased inhibitory activities of the
branched linker substituents contained in valproyl-
and pivaloylcarnitine (Table 1) might indicate a
spatial restriction executed by hOCTN2 in the linker
region.
The ammonium ion is crucial for recognition as can be
seen from the complete inactivity of dimethylamino-
butyric acid. To further evaluate the individual
requirements of the two linked functional groups, a
second set of compounds, either comprising a deriv-
atized neutral carboxylic acid functionality or no such
functionality, was selected (Table 2). If the ammonium
functionality comprises at least two methyl substitu-
ents, an inverted ester separated by two atoms is well
tolerated and even a branched isopropyl substituent
(ipratropium bromide) or a bridge between two
substituents (pancuronium bromide) of the charged
nitrogen is still accepted by hOCTN2. Surprisingly, in
scopolamine derivatives, there is a striking difference
between the very well-recognized N-methyl com-
pound and the more voluminous, but almost inactive,
N-butyl derivative. A search through the PDB data-
base [38] revealed a high preference for electron-rich
aromatic side chains like tyrosine or tryptophan
enclosing an ammonium functionality. Lengthy and
more voluminous substituents like the N-butyl group
might adversely interfere with a close contact between
amino acid side chains and the ammonium function-
ality, and therefore hamper the recognition of scopol-
amineN-butyl bromide. A shortened two-atom linker
between the ammonium functionality and an inverted
ester is not tolerated in rather small molecules
(Table 2, acetyl choline) and likewise introduction of
a carbamate functionality is absolutely detrimental for
recognition by hOCTN2 (Table 2, carbamylcholine,
neostigmine). Absence of a carboxylic acid function-
ality also leads to non-recognition by the transporter
(Table 2, decamethonium bromide).
A constant positive charge can reside not only in an
ammonium ion but also in a heteroaromate as, for
example, in cephaloridine that has been shown to
interfere with L-carnitine transport by hOCTN2
[27]. To further assess the capability of hOCTN2 to
transport various positively charged heteroaromates,
we selected compounds comprising such an entity
but lacking further constantly positive charged
functionalities (group 3). The two charged cephalo-
sporin derivatives showed either no (Table 3, cefta-
zidime) or only borderline activity (cefozoprane),
despite the presence of a charged carboxylate group
separated by a three-atom linker (ceftazidime). Of
the other selected examples (Table 3), none showed
significant activity, which could indicate a steric
Table 2. Inhibition of hOCTN2 by substances carrying an ammonium ion and a carboxylic acid group or a derivative thereof. Substances
were selected and tested for hOCTN2 inhibition as described in Methods. Inhibition was scored as described in Table 1.
Substance Carnitine transport (% of
control, inhibitor 100 mM)
Carnitine transport (% of
control, inhibitor 1000 mM)
Functional group closest to ammonium
nitrogen (distance in atoms)
Efficacy of
inhibitor
Atropine methyl
bromide
674 244 Inverted ester (3) ++
Anisotropine
methyl bromide
9311 479 Inverted ester (3) ++
Ipratropium
bromide
382 292 Inverted ester (3) ++
Scopolamine
methyl bromide
75112 203 Inverted ester (3) ++
Scopolamine N-
butyl bromide
1036 1025 Inverted ester (3) –
Pancuronium
bromide
932 592 Inverted ester (2) +
Acetylcholine 855 833 Inverted ester (2) –
Carbamylcholine
chloride
1021 942 Inverted ester (2) –
Decamethonium
bromide
883 919 None –
Neostigmine
bromide
914 8511 Carbamate (3) –
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handicap of the disc-shaped heteroaromates that
cannot be properly recognized by the ”active site” in
hOCTN2.
Since cephaloridine is a known inhibitor of L-carni-
tine transport by hOCTN2 [27], it was more than
tempting to check whether the cephalosporin scaffold
per se without bearing a constant charge is recognized
by the transporter. This question can be clearly
negated since none of the eight tested cephalosporin
or penicillin derivatives showed significant interfer-
ence with the L-carnitine transport (Table 4). After
exclusion of direct interactions between cefalotin and
carnitine, the most likely reason for the observed
stimulation of carnitine transport by cefalotin is an
allosteric interaction with OCTN2, an assumption
needing more detailed studies to be proven. So far, no
other compounds with such properties have been
described.
Not obeying the rules mentioned so far, verapamil
(Fig. 1C) was identified as a strong inhibitor of
hOCTN2 (Table 4 and Fig. 5). This molecule com-
prises neither a constantly charged nitrogen ion nor a
carboxylic acid derivative separated by a three-atom
linker. The inhibitory effect of verapamil on carnitine
transport has been described in an oocyte system with
hOCTN2 expression [34] and in heart and skeletal
muscle explants [39], but themechanisms of inhibition
are so far not clear. It cannot be completely excluded
that the tertiary nitrogen, in combination with the
nitrile group, could be mimicking a pair of pharma-
cophores that are strongly recognized by hOCTN2.
Alternatively, verapamil might be acting via an
allosteric inhibitor and thereby not directly interfere
with L-carnitine recognition and transport by
hOCTN2.
Further studies are therefore necessary to understand
the relationship between structure and inhibitory or
stimulatory capacity of drugs and chemicals towards
hOCTN2. Since inhibition of hOCTN2 by chemical
compounds can be associated with systemic carnitine
deficiency [27, 34], identification of hOCTN2 inhib-
itors appears to be clinically important. Our model
provides the basis for identification and rapid screen-
ing of possibly interacting substances, but the clinical
relevance of hOCTN2 inhibition observed in vitro
needs to be studied in animals or humans in vivo. It has
also to be taken into account that inhibition of
hOCTN2 is not the only mechanism associated with
secondary carnitine deficiency [26, 34].
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